Clinical trials: Other Hematologic Malignant Neoplasms
Acute Myeloid Leukemia
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Long term disease-free survival (DFS) of patients with acute myeloid leukemia (AML) is still poor. Recently, so-called "targeted therapy" for cancer has been introduced to the treatment of patients with AML.
- Trial name
- PAZOPANIB-AML (NCT01361334)
- Testing
- Pazopanib
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Muenster
Nasopharyngeal Neoplasms, Salivary Gland Diseases
A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
RATIONALE Radiotherapy is the primary therapeutic strategy for nasopharyngeal carcinoma. Radiotherapy may cause adverse effect such as xerostomia and mucositis.
- Conditions
- Nasopharyngeal Neoplasms, Salivary Gland Diseases, Bone Marrow Diseases, Mucositis
- Trial name
- NCT01762514
- Testing
- Amifostine every-other-day regimen, Amifostine everyday regimen
- Where
- 7 sites in China
- Volunteers
- 360 people
- Sponsor
- Sun Yat-sen University
Cancer
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation.
- Trial name
- NCT00008359
- Testing
- caspofungin acetate, liposomal amphotericin B
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01139333
- Testing
- gene expression analysis, western blotting, flow cytometry
- Volunteers
- 52 people
- Sponsor
- Children's Oncology Group
Leukemia
Studying Gene Expression in Tissue Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01057303
- Testing
- RNA analysis, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT
To evaluate if hyper-fractionated TBI or TMLI followed by Treg/Tcon adoptive immunotherapy improve cGvHD/disease free survival after allogeneic HSCT in patients affected by high-risk acute leukemias or other hematologic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myeloproliferative Disorders, Lymphoma
- Trial name
- NCT03977103
- Testing
- High dose irradiation conditioning + Treg/Tcon
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- University Of Perugia
Kidney Cancer, Leukemia
Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation
RATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem cell transplantation.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00080873
- Testing
- Traumeel S
- Where
- 44 sites in United States, Australia and 2 more
- Volunteers
- 195 people
- Sponsor
- Children's Oncology Group
Multiple Myeloma, Multiple Myeloma in Relapse
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse
- Trial name
- NCT01435720
- Testing
- SNS01-T
- Where
- 7 sites in United States, South Africa
- Volunteers
- 15 people
- Sponsor
- Senesco Technologies, Inc.
Drug/Agent Toxicity by Tissue/Organ, Leukemia
High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Deoxycytidine may protect patients from the side effects of high-dose cytarabine.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002818
- Testing
- cytarabine, deoxycytidine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Virginia Commonwealth University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
RATIONALE: Giving chemotherapy before a donor peripheral stem cell transplant or bone marrow transplant using stem cells from a brother or sister that closely match the patient's stem cells, helps stop the growth of cancer or…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00438958
- Testing
- filgrastim, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 230 people
- Sponsor
- The Canadian Blood and Marrow Transplant Group
Bladder Carcinoma, Breast Cancer
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Background: Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies.
- Conditions
- Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer
- Trial name
- NCT02457650
- Testing
- Cyclophosphamide, Fludarabine, Anti-NY ESO-1 TCR-transduced T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Second People's Hospital
Multiple Myeloma
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.
- Trial name
- NCT05137054
- Testing
- Linvoseltamab, Daratumumab, Carfilzomib
- Where
- 42 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Regeneron Pharmaceuticals
Brain and Central Nervous System Tumors, Leukemia
Metabolic Syndrome in Childhood Cancer Survivors
RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood cancer may help doctors learn more about the disease.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Metabolic Syndrome
- Trial name
- NCT00920738
- Testing
- metabolic assessment, questionnaire administration
- Where
- United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Chronic Myeloproliferative Disorders, Infection
Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
RATIONALE: Antifungal therapy with liposomal nystatin may reduce fever and neutropenia in patients undergoing treatment for hematologic cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma
- Trial name
- NCT00002742
- Testing
- amphotericin B deoxycholate, nystatin
- Where
- 59 sites in United States
- Sponsor
- Aronex Pharmaceuticals
Leukemia
Biomarkers in Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01138319
- Testing
- DNA analysis, mutation analysis, polymerase chain reaction
- Volunteers
- 18 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
This is a Phase 1, 2-part, open-label, multicenter, first-in-human (FIH) study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TAS1553 administered orally to participants…
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04637009
- Testing
- TAS1553
- Where
- 10 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Leukemia
Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01298414
- Testing
- RNA analysis, laboratory biomarker analysis
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Prostate Cancer, Pesticide Exposures
Agriculture Health Study
The "Agricultural Health Study" (AHS) is a collaborative effort between the National Cancer Institute and the National Institute of Environmental Health Sciences. The U.S.
- Conditions
- Prostate Cancer, Pesticide Exposures, Lymphoma, Multiple Myeloma
- Trial name
- NCT00352924
- Where
- United States
- Volunteers
- 89,655 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
- Trial name
- MAGNETISMM17 (NCT05462639)
- Testing
- Elranatamab (PF-06863135)
- Where
- 36 sites in United States, Canada
- Sponsor
- Pfizer
Lymphoma
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: Studying samples of blood in the laboratory from patients who have undergone a donor bone marrow transplant may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- NCT00898612
- Where
- United States
- Sponsor
- Mayo Clinic